Sadoff J, Hwang S, Rosenfeld D, Ettinger L, Spigland N
Department of Surgery, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, USA.
J Pediatr Surg. 1997 Jun;32(6):860-3. doi: 10.1016/s0022-3468(97)90636-9.
Pancreatitis has been noted to be a potential complication in 2% to 16% of patients undergoing treatment with L-asparaginase for a variety of pediatric neoplasms, but rarely has surgical intervention been necessary. The authors present two fulminant cases of L-asparaginase-induced pancreatitis and review the current literature. The first patient is a 15-year-old boy who underwent induction chemotherapy with L-asparaginase for non-Hodgkin's lymphoma with bone marrow involvement. He presented with diffuse patchy necrosis of the pancreas as well as a large infected pancreatic pseudocyst. He subsequently required operative debridement of the pancreas and external drainage of the pseudocyst. He is currently doing well. The second patient is a 5-year-old boy who was treated with L-asparaginase for a diagnosis of acute lymphocytic leukemia. Within 3 weeks of initiation of therapy, fulminant pancreatitis developed, which progressed to multisystem organ failure. Computed tomography scan demonstrated extensive pancreatic necrosis involving 90% of the gland. He underwent surgical debridement of his necrotic pancreas and wide drainage of the lesser sac. Postoperatively he improved but subsequently multiple complications developed including erosion of his gastroduodenal artery with significant intraabdominal bleeding, which was controlled with angiographic embolization. Subsequently erosion of his endotracheal tube into the innominate vein developed, and he died. L-asparaginase-induced pancreatitis has been described after therapy for various pediatric neoplasms, and the reported cases have usually been self-limiting. However, our cases demonstrate potentially fatal sequelae of this complication and mandate early diagnosis with appropriate surgical intervention in this setting.
胰腺炎被认为是接受L-天冬酰胺酶治疗各种小儿肿瘤的患者中2%至16%可能出现的并发症,但很少需要手术干预。作者报告了两例L-天冬酰胺酶诱导的暴发性胰腺炎病例,并回顾了当前文献。第一例患者是一名15岁男孩,因骨髓受累的非霍奇金淋巴瘤接受L-天冬酰胺酶诱导化疗。他出现胰腺弥漫性片状坏死以及一个大的感染性胰腺假性囊肿。随后他需要进行胰腺手术清创和假性囊肿外引流。他目前情况良好。第二例患者是一名5岁男孩,因诊断为急性淋巴细胞白血病接受L-天冬酰胺酶治疗。在开始治疗的3周内,暴发性胰腺炎发展,进而发展为多系统器官衰竭。计算机断层扫描显示广泛的胰腺坏死,累及90%的腺体。他接受了坏死胰腺的手术清创和小网膜囊广泛引流。术后他有所改善,但随后出现多种并发症,包括胃十二指肠动脉侵蚀伴腹腔内大量出血,通过血管造影栓塞得以控制。随后气管导管侵蚀入无名静脉,他死亡。L-天冬酰胺酶诱导的胰腺炎在治疗各种小儿肿瘤后已有描述,报告的病例通常为自限性。然而,我们的病例显示了这种并发症潜在的致命后果,并要求在这种情况下进行早期诊断并采取适当的手术干预。